COPD (Chronic Obstructive Pulmonary Disease) Clinical Trial
Official title:
A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
This is a Phase III randomized, double-blind, parallel group, multi-center event-driven study comparing BGF MDI 320/14.4/9.6 μg BID with GFF MDI 14.4/9.6 μg BID in participants with COPD who are at risk of a cardiopulmonary event. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05553847 -
Automated Oxygen Titration in Daily Life in Patients With COPD on Home Oxygen
|
N/A | |
| Completed |
NCT02859194 -
The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients
|
N/A | |
| Not yet recruiting |
NCT03921983 -
Non Invasive Evaluation of Muscle Hypoxia in COPD Patient (EVANIMUS)
|
N/A | |
| Recruiting |
NCT05572632 -
Rehabilitation in Safety-net Environments (RISE) to Improve Outcomes in Vulnerable Patients With COPD
|
N/A | |
| Recruiting |
NCT06075095 -
A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD
|
Phase 3 | |
| Not yet recruiting |
NCT06158633 -
A Pilot Observation and Feasibility Study of Prevora, Integrated Into Homecare Visits of High-risk Adults
|
||
| Recruiting |
NCT05811832 -
Evaluation in Elderly Individuals With Chronic Obstructive Pulmonary Disease(COPD)
|
||
| Completed |
NCT03197818 -
Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
|
Phase 3 | |
| Completed |
NCT02867761 -
RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative
|
Phase 3 |